Business & Regulation

Dissecting a ligand into smaller fragments can provide a strategy for analyzing the role of key functional groups in a protein-ligand interaction.

Abusers are finding ways to circumvent current abuse-deterrent measures, leaving companies in need of new strategies.

The December issue will feature our inaugural Innovation Awards, recognising the most exciting new technologies of 2015.

Sitting Down With… Carsten Brockmeyer, CEO, Formycon, Germany.

The US Centers for Disease Control and Prevention has officially declared an “epidemic of prescription drug abuse”.

A round-up of the latest expansion plans and new facilities as building fever grips the industry

Big pharma is turning to outside sources to fill pipelines, but how often are companies backing the wrong horse?

How did the NIH get it so wrong – and how can it move on?

Rising drug prices are not helping the industry’s image problem.

Pharmaceutical and regulatory professionals around the world must speak the same language.